Beauty Health Co (SKIN) is expected to report a Q3 2026 consensus revenue of $67.97 million and an EPS of -$1.32, with the current stock price of $10.38 trading below the average analyst target of $15.67.
Investors are primarily focused on the resilience of consumables revenue, which represents the critical recurring component of the company's "razor-and-blade" business model.
Following a 1-for-20 reverse stock split in October 2026, the company is under pressure to stabilize its financial position as equipment sales for its HydraFacial delivery systems continue to face macroeconomic headwinds.
Analysts are also monitoring the progress of the company's China distributor transition and its roadmap toward achieving positive adjusted EBITDA ahead of an anticipated return to growth in 2027.